AdventHealth partners with Helix for a 10,000-patient DNA sequencing trial

23-Mar-2020
KEY POINTS FROM ARTICLE:

WholeMe is the first genomics project by AdventHealth (AH), to partner with Helix.
It is a clinical trial to sequence DNA of 10,000 Floridians.
Goal is to better prevent, diagnose, and treat diseases, like hypercholesterolemia.
Helix uses Next Generation Sequnecing (NGS) to sequence a proprietary assay called Exome+.
That provides 100 times more data than was previously available.
Helix will sequence each participant’s DNA sample once, then securely store information.
This enables user to explore many DNA-powered applications throughout their lifetime.
AH recruited any adult 18 or older, and located in the central Florida community.
They can withdraw consent any time and request anonymity and deletion of genetic data.
To include small subgroup of 750 people that already had experienced a cardiac event.
In attempt to determine if genetic testing and the counseling can improve their cases.
Currently, no scheduled end date yet, and at 67 percent of its recruitment goal.

A big study to look forward as it intends to improve disease prevention, diagnosis, and management

Mentioned in this article:

Resource AdventHealth - Multi-state health care network

Resource Exome+ - proprietary approach sequencing technology, Helix

Resource Helix - American population genomics company

Resource LifeOmic - Software company

Resource Rebecca Essner - Data scientist and geneticist at AdventHealth

Resource Steven Smith - Chief Scientific Officer, AdventHealth

Read full article on Clinical Leader website
More Quantified Self information, news and resources
More Big Data information, news and resources